screening procedure. The Cliitek 200/Multistix 9 pH method produces results in increments of 0.5 pH unit, whereas a standard laboratory pH meter can give results that are reliable to the nearest 0.1 pH unit or less. In our study, the Clinitek results deviated markedly from true pH values for both acidic and alkaline urines. These drawbacks could cause problems in laboratory evaluation of renal tubular acidosis, a group of disorders characterized by decreases in renal excretion of acid, resulting in systemic hyperchioremic acidosis and a relatively alkaline urine. Patients with distal renaltubular acidosis cannot acidify their urine below pH 6.0 (some physicians consider the cutoff point to be pH 5.5), even when systemic acidosis is intentionally produced by an oral ammomum chloride loading test (11). if a reported urine pH was <5.5, a diagnosis for this disorder would normally be excluded, yet the Cliitek method could easily yield a result of 5.5 or even 5.0 for a urine specimen with a true pH 6.0.
Clinical Utility of Ektachem#{174}-Determined Bilirubin Fractions for Classifying Adult Inpatients
Gregory A. Tetrault, Barbara A. Melklejohn, and Charles E. Sparks' We determined total bilirubin, "direct" and "indirect" bilirubin fractions, and, in parallel, using Ektachem slides, the total, conjugated, unconjugated, and delta bilirubin contents for specimens from 88 adult inpatients at various times during hospitalization in a tertiary-care facility. We wanted to see if the results correlated with the patients' diagnoses, based on a review of medical records and other laboratory data. The patients (including some with mixed disease types) were assigned to one of three predominant disease-process groups: obstructive liver disease, parenchymal liver disease, or hemolytic disease. Ektachem bilirubin fractions and the comparable total, "direct," and "indirect" bilirubin fractions showed equal sensitivity in screening and monitoring disease in all three groups. Measurements of conjugated bilirubin, unconjugated bilirubin, and their sum were sufficient for evaluating bilirubin abnormalities in this complex patient population. Determining delta bilirubin with the total bilirubin Total serum bilirubin comprises conjugated and unconjugated bilirubin (Bc and Bu), which are mostly noncovalently bound to serum proteins, and delta biirubin (Bd), which is covalently bound to serum proteins (3). Previous reports have shown that conjugated bilirubin measured by the Ektachem Bu/Bc slideis better than directbilirubin for evaluating patientswith hepatobiliary disease (4, 5). Measurement of delta bilirubin [TBIL -(Bu + Bc)l, which consists primarily of conjugated bilirubin covalently bound to albumin, has only limited clinical usefulness in most adult patients (4). Therefore, if Bu and Bc provide sufficient clinical information in patients with high concentrations of bilirubin in serum, then laboratories using Ektachem instrumentation can replace "direct,"
"indirect," and total bilirubin determinations with Bc, Bu, and Buc, reserving TBIL measurements for cases when jaundice may be the result of significant increases in Bd. Here we report our examination of this premise, based on results for 88 adult inpatients.
Materials and Methods
Specimens were obtained from adult inpatients for whom the following panel of tests had been ordered: total protein, albumin, calcium, phosphorus, serum urea nitrogen, creatinine, urate, aspartate aminotransferase (AST), lactate dehydrogenase (LD), alkaline phosphatase (ALP), TBIL, and cholesterol, performed with a Parallel Analytical System (Amerian Monitor Corp., Indianapolis, IN 46268). The specimens were obtained at various times during hospitalization and at different stages of disease, not just at admission. All specimens with increased TBIL (>10 mg/L) were included in the study. In addition, specimens with TBIL between 5 and 10 mg/L were included if both of the following criteria were fulfilled: (a) an increase of AST, ALP, or LI),
and (b) an increase of alanine aminotransferase (ALT;
performed in addition to the panel tests). Specimens included in the study then underwent further analyses: for gamma-glutamyltransferase (GGT), ALT, and DBIL by the Parallel discrete analyzer, and for TElL, Bu, and Bc by a Kodak Ektachem 400 or 700 analyzer (Eastman Kodak Co., Rochester, NY 14650).
Review of the medical records for the 100 patients initially included in the study allowed classification of 88 patients into one of three groups: obstructive liver disease (n = 20), parenchymal liver disease (n = 15), and hemolytic disease (n = 53)3 Assignment to a group was based on clinical history, physical examination, imaging studies (abdominal roentgenograms, computed tomographic scans, ultrasonography, and HIDA scans), laboratory findings (biochemical, hematological, and microbiological), and surgical pathology results (cholecystectomy specimens, liver biopsies, bone marrow biopsies, lymph node biopsies, etc.). Many of the patients had complex or mixed disease processes(e.g., mixed diseases (and the number of affectedpatients)in eachgroup were as follows:obstructiue-cholelithiasis(9), obstruction due to tumor (3), obstruction due to>loal inflammation, swelling, or hematoma (4), other (4);. prenchymal-cirrhosis (5), alcohol or drug-induced hepatitis (5), primary or metastatic carcinoma (4), Gilbert's syndrome (1); hemolytic-hemolysis (sickle-cell crises, bums, thrombotic thrombocytopenic purpura) (9), hematological malignancy with multiple transfusions (8), multiple transfusions of erythrocytes after bleeding (14), carcinoma requiring transfusions (5), sepsis(6), other (11) .
obstructive and parenchymal liver disease, hematologic malignancy with hepatotoxic chemotherapy), making assignment to a single classification difficult. In those caseswe based the assignment on the disease process thought to be most important clinically or most responsible for the abnormal clinical chemistry test results. Patients with moderate to severe renal disease (n = 6) and patients with diseases that could not be assigned to one of the three groups (n = 6) were excluded. We were able to obtain follow-up specimens from 31 of the study patients.
Normal reference intervals for all tests were determined by analysis of blood-donor samples obtained from the American Red Cross.
Results
Linear was between IBIL and Bu in patients with obstructive liver disease (P <0.05, chi-squared goodness of fit test).
In the 48 follow-up specimens obtained from 31 of the study patients 0 to 21 days (mean 5.3 days) after the first specimen, significant changes in TBIL follow-up values were always accompanied by corresponding changes in Euc values. The magnitudes of both the absolute and relative changes in TBIL and Buc were not significantly different (paired t-tests, P <0.05). However, changes in Bd values did not correspond to those of TElL (paired t-test, P >0.05).
DIscussion
These results show that the Ektachem tests for bilirubin (TBIL, Bu, and Bc) are as sensitive in the evaluation of hepatobiliary disease and hemolytic processes as standard bilirubin tests performed with a Parallel Analytical System. The data also support the conclusion that bilirubin values determined with only the Eu/Bc slide (Bu, Be, and Buc) are sufficient for use in the diagnosis and follow-up of adult patients with hepatobiliary and hemolytic diseases. In all three disease categories, there was no significant difference in sensitivity between Buc and TBIL. Only six patients with an increase in TBIL had normal Eu, Bc, and Buc values. Two patients recovering from cholelithiasis and three patients in the hemolytic category with multiple recent transfusions had slight to moderate Ed increases. One patient with ovarian carcinoma had a slight increase of Bd that fell to within normal limits in five days. No cases of acute hepatobiliary disease or significant hemolysis or hemoglobin breakdown would have been missed by omitting TBIL.
Evaluation of the 48 follow-up specimens showed that changes in TElL were reflected by changes in Buc. & and Bu bilirubin fractions can replace measurement of "direct" and "indirect" bilirubin. The increased sensitivity in this study of IBIL compared with Bu in patients with obstructive disease has little clinical significance, because conjugated bilirubin is the fraction of importance in hepatobiiary obstruction. Running the total-bilirubin slide is not required when screening adult patients, because delta bilirubin is not useful in the initial evaluation of adult patients with hepatobiliary or hemolytic disease. However, delta bilirubin may be useful in ruling out clinical disease in patients with prolonged jaundice because this fraction stays increased longer than noncovalently protein-bound fractions (3, 4). (7)]. Discrepancies between Buc and TBIL can cause significant errors in the calculation of Bd, occasionally resulting in a "negative" value of Ed (unpublished data). The single-slide method can eliminate that problem. Significant costs savings may also be achieved by running only the Ektachem Bu/Bc slide for routine bilirubin testing. Bilirubin metabolism in children and older infants is generally the same as in adults, and bilirubin testing in this population can be handled as in adult patients (8). Studieshave shown that the Ektachem Eu/Bc slide alone is ideal for neonatal bilirubin testing because of the small sample volume required (10 pL) and the absence of hemoglobin interference (3, 6, 9). Therefore, routine bilirubin testing in all patient populations can be validly accomplished by using only the Ektachem Eu/Bc slide.
We thank Dr. Dean Aryan for critical reading of the manuscript.
